Association Between Migraine and Suicidal Behaviors: A Nationwide Study in the USA

Friedman, Lauren E.; Zhong, Qiu‐Yue; Gelaye, Bizu; Williams, Michelle A.; Peterlin, B. Lee

doi:10.1111/head.13235

Cited by 13 publications

(31 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Migraine may be associated with increased risk of suicidal ideation or behavior as reported by several studies [ 8 , 9 , 37 ]. In the current study, nearly 17% of the patients had comorbid depression, but treatment-emergent suicidal behavior was not reported.…”

Section: Discussionmentioning

confidence: 98%

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

et al. 2018

View full text Add to dashboard Cite

BackgroundGalcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functioning. This study evaluated the safety and tolerability, as well as the effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine.MethodsPatients diagnosed with episodic or chronic migraine, 18 to 65 years old, that were not exposed previously to galcanezumab, were randomized to receive galcanezumab 120 mg or 240 mg, administered subcutaneously once monthly for a year. Safety and tolerability were evaluated by frequency of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to study discontinuation. Laboratory values, vital signs, electrocardiograms, and suicidality were also analyzed. Additionally, overall change from baseline in the number of monthly migraine headache days, functioning, and disability were assessed.ResultsOne hundred thirty five patients were randomized to each galcanezumab dose group. The majority of patients were female (> 80%) and on average were 42 years old with 10.6 migraine headache days per month at baseline. 77.8% of the patients completed the open-label treatment phase, 3.7% of patients experienced an SAE, and 4.8% discontinued due to AEs. TEAEs with a frequency ≥ 10% of patients in either dose group were injection site pain, nasopharyngitis, upper respiratory tract infection, injection site reaction, back pain, and sinusitis. Laboratory values, vital signs, or electrocardiograms did not show anyclinically meaningful differences between galcanezumab dosesOverall mean reduction in monthly migraine headache days over 12 months for the galcanezumab dose groups were 5.6 (120 mg) and 6.5 (240 mg). Level of functioning was improved and headache-related disability was reduced in both dose groups.ConclusionTwelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days. Safety and tolerability of the 2 galcanezumab dosing regimens were comparable.Trial registrationClinicalTrials.gov as NCT02614287, posted November 15, 2015. These data were previously presented as a poster at the International Headache Congress 2017: PO-01-184, Late-Breaking Abstracts of the 2017 International Headache Congress. (2017). Cephalalgia, 37(1_suppl), 319–374.

show abstract

Section: Discussionmentioning

confidence: 98%

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Operationalizing income status via method of payment for services-specifically Medicaid as a proxy for low-income status-is an established approach in the literature (e.g., Buck, Msall, Schisterman, Lyon, & Rogers, 2000;Hurt & Betancourt, 2015;Marcin, Schembri, & Romano, 2003;Schechter & Margolis, 1998) and has been used in studies utilizing HCUP data (e.g., Albrecht et al, 2010;Correa, Bardenheier, Elixhauser, Geiss, & Gregg, 2015). Based on previous studies, the analysis also controlled for multiple covariates (e.g., Correa et al, 2015;Friedman, Zhong, Gelaye, Williams, & Peterlin, 2018;Jinjuvadia et al, 2018), including age (continuous), urbanicity of patient (1 = central urban, 2 = suburban, 3 = exurban, 4 = rural, 5 = micropolitan, 6 = other), and hospital region of the county (1 = Northeast, 2 = Midwest, 3 = South, 4 = West).…”

Section: Methodsmentioning

confidence: 99%

Posttraumatic Stress Disorder Among Low‐Income Adolescents Experiencing Family–Neighborhood Income Disparities

Carbone

Holzer

Vaughn

2019

Journal of Traumatic Stress

View full text Add to dashboard Cite

Certain neighborhood factors may increase the risk of exposure to trauma, therefore increasing the risk of posttraumatic stress disorder (PTSD). Other aspects of neighborhoods can be protective, such as neighborhood-based social relationships, which provide social support that buffers the risk of developing PTSD. The strength of these social relationships may not be as dependent on neighborhood conditions as much as they are contingent on socioeconomic similarities between neighborhood residents. Using a nationally representative sample of hospital emergency department admissions in the United States (N = 13,669,251), this study hypothesized that an interaction between family-level income and neighborhood-level income would be associated with adolescent PTSD. The results show that female adolescents who resided in the highest income areas were 1.39 times more likely, 95% CI [1.09, 1.77], to be diagnosed with PTSD than those who lived in the lowest income areas. This association was not statistically significant for male adolescents. Additionally, low-income female youth were nearly one-third more likely than their non-low-income counterparts to be diagnosed, odds ratio (OR) = 1.29, 95% CI [1.12, 1.48], whereas low-income male youth were nearly twice as likely than their non-low-income counterparts to be diagnosed, OR = 1.95, 95% CI [1.62, 2.34]. Furthermore, there was an interaction among both male and female adolescents such that lower-income adolescents living in higher-income areas had higher odds of a PTSD diagnosis compared to their higher-income peers in areas that were in the same median household income quartile.

show abstract

“…[88][89][90][91] SM may also increase the risk of suicidality. [88][89][90][91] SM may also increase the risk of suicidality.…”

Section: Expert Opinionmentioning

confidence: 99%

“…Studies in both the adult and pediatric population suggest a link between migraine and suicidal behavior, with an increased association seen in those with chronic migraine and migraine with aura. [88][89][90][91] SM may also increase the risk of suicidality. A population-based study of adult Taiwanese patients diagnosed with either SM (n = 13,605) or migraine (n = 21,485) found that those with SM had a 1.81-fold risk of attempting suicide compared to a control group that did not have either diagnosis.…”

Section: Expert Opinionmentioning

confidence: 99%

Status Migrainosus in Children and Adults

2019

View full text Add to dashboard Cite

Association Between Migraine and Suicidal Behaviors: A Nationwide Study in the USA

Cited by 13 publications

References 41 publications

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Posttraumatic Stress Disorder Among Low‐Income Adolescents Experiencing Family–Neighborhood Income Disparities

Status Migrainosus in Children and Adults

Contact Info

Product

Resources

About